,
,
,
,
,
,
, Réflexion sur la stratégie de développement et d'enregistrement internationale, p.49
50 3.2.1 Soutient et opportunités réglementaires en amont de l'enregistrement ,
,
,
,
, , vol.87
,
,
, InfoCancer-ARCAGY-GINECO-Localisations-Cancers du sang-Hémopathies-Leucémie Myéloïde
,
,
, Cancers du sang-Hémopathies-Myélome Multiple (MM)-Maladie-Les lymphocytes, 2017.
est-ce que le myélome multiple ?-Société canadienne du cancer ,
,
, , 2017.
, , 2015.
, Cancers du sang-Hémopathies-Myélome Multiple (MM), 2017.
,
Diagnosis and Treatment, Mayo Clin Proc, vol.91, issue.1, pp.101-119, 2016. ,
,
,
,
,
, Haute Autorité de Santé-ALD n° 30-Myélome multiple. Guide patient-affection longue durée-La prise
,
, Haute Autorité de Santé-ALD n° 30-Myélome multiple. Guide patient-affection longue durée-Tumeur
, Juillet, 2018.
,
Current therapeutic strategies for multiple myeloma, International Journal of Clinical Oncology. 2015, vol.20, issue.3, pp.423-430 ,
, Heads of Medicines Agencies: MRI Product Index, 2018.
, European Medicines Agency-Find medicine-European public assessment reports
, Juillet, 2018.
,
, Drugs Approved for Multiple Myeloma. National Cancer Institute
,
, Multiple Myeloma: Treatment Options, Cancer.Net, 2018.
How is patient care for multiple myeloma advancing? Expert Review of Hematology, vol.10, pp.551-561, 2017. ,
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012, European Journal of Cancer, vol.49, pp.1374-1403, 2013. ,
, Worldwide data | World Cancer Research Fund International
,
, , 2017.
, , 2017.
, Orphanet | Prévalence des maladies rares par ordre alphabétique
,
,
Estimation nationale de l'incidence des cancers en France entre 1980 et 2012-Partie 2 : Hémopathies malignes, 2013. ,
, , 2014.
,
, Key Statistics for Multiple Myeloma, 2018.
, , 2018.
,
, Myeloma statistics | Cancer Australia, 2018.
,
Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma, Blood Cancer Journal. 2015, vol.5 ,
, HOME. Cancer information Service
,
Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study, American Journal of Hematology, vol.89, issue.7, pp.751-756, 2014. ,
, Facteurs de risque du MM-Société canadienne du cancer
,
,
Risk of Progression and Survival in Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study, Leukemia. 2012, vol.26, issue.1, pp.149-157 ,
Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ?3 ,
, Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or
, Double Refractory to a PI and an IMiD, Oncologist. 2016, vol.21, issue.11, pp.1355-1361
Difficult to swallow: issues affecting optimal adherence to oral anticancer agents, Am Soc Clin Oncol Educ Book, vol.2013, pp.265-270 ,
Adherence to therapy with oral antineoplastic agents, J Natl Cancer Inst, vol.94, pp.652-661, 2002. ,
Interventions to promote adherence with oral agents, Semin Oncol Nurs, vol.27, pp.133-141, 2011. ,
Global Pharmaceutical and Biologics Regulatory Strategy. The Regulatory Affairs Professionnals Society, 2016. ,
, European Medicines Agency-Overview-Supporting SMEs, 2017.
,
, European Medicines Agency-Research and development-PRIME: priority medicines
, European Medicines Agency-Factsheet: PRIME at a glance
,
, European Medicines Agency-List of products granted eligibility to PRIME
, Juillet, 2018.
Guidance for Industry Expedited Programs for Serious Conditions-Drugs and Biologics ,
, Novembre, 2017.
, Approval Reports-Breakthrough Therapy Approvals
NDA and BLA Approval Reports-Fast Track Approvals for Drugs ,
Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. Plos one, 2015. ,
, European Medicines Agency-Orphan designation-Applying for orphan designation
,
,
, European Medicines Agency-Human medicines-Rare disease (orphan) designations
,
,
, FDA Orphan Drug Designation 101
, Orphan Drug Regulations, 2018.
Labour and Welfare. The Article 77-2 of the Pharmaceutical Affairs Law ,
Labour and Welfare: Pharmaceuticals and Medical Devices ,
HD-Guidance document Orphan Drug, 2017. ,
, , pp.2-2
Médicaments importants pour des maladies rares, 2018. ,
,
, Federal Register of Legislation-Australian Government, 2017.
,
, Australian Government Department of Health Therapeutic Goods. Orphan Drug Program Reforms, 2017.
, Australian Government Department of Health Therapeutic Goods. Orphan Drug Designation Eligibility Criteria, Therapeutic Goods Administration (TGA)
,
, Australian Government Department of Health Therapeutic Goods. Orphan drug designation A step-by-step guide for prescription medicines, Therapeutic Goods Administration (TGA)
,
, Australian Government Department of Health Therapeutic Goods. Orphan Drug Designation prior to 1, Therapeutic Goods Administration (TGA), 2017.
,
, Addendum to ICH E11: clinical investigation of medicinal products in the pediatric population E11 (R1)
, EMA/973755/2011-European Medicines Agency decision, 2018.
,
Guidance for Industry How to Comply with the Pediatric Research Equity Act ,
Adult-Related Conditions that qualify for a waiver because they rarely or never occur in pediatric, 2018. ,
, EU 10-Eudralex-VOLUME 10-Rules for governing medicinal products in the European Union
,
,
New Regulatory Landscape for clinical trials in Russia ,
, Septembre, 2017.
,
, Regulation (EU) No 536/2014 of the European Parliament and of the council-Clinical Trial Regulation of
, Clinical Trials on Medicinal Products for Human Use, 2014.
Investigational New Drug (IND) Application ,
Pre-IND Consultation Program, 2017. ,
,
Guidance for Industry Formal Meetings Between the FDA and Sponsors or Applicants ,
, European Medicines Agency-Research and development-Scientific advice and protocol assistance
,
, European Medicines Agency-Scientific advice and protocol assistance-How to submit a scientific advice or protocol assistance request. Pre-submission meeting, 2017.
, , 2017.
,
, European Medicines Agency-Human regulatory-Marketing autorisation
,
, European Medicines Agency-Marketing authorisation-Pre-authorisation guidance
, Juillet, 2018.
, The Drug Development Process-Step 4: FDA Drug Review
,
New Drug Application (NDA) ,
,
, Points to Be Considered by the Review Staff Involved in the Evaluation Process of New Drug (FINAL)
,
, Reviews | Pharmaceuticals and Medical Devices Agency, 2018.
,
Comment les médicaments sont examinés au Canada. Éducation et sensibilisation ,
HD-Guidance document. Authorisation human medicine under Art. 13 ATP ,
, Juillet, 2018.
, Australian Government Department of Health Therapeutic Goods. Prescription Medicines Registration Process, Therapeutic Goods Administration (TGA)
,
, Medsafe's Evaluation and Approval Process, 2018.
,
, Registraton of medicines in the eurasian economic union
, Juillet, 2018.
, SAHPRA-South African Health Products Regulatory Authority, 2018.
,
, Department of health. Medicines and related substances Act
,
, , 2018.
, Distribution and Marketing of Drugs in Brazil: Overview
,